Experimental combo therapy aims to stop leukemia return after transplant

NCT ID NCT06735690

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) is safe and feasible for 15 people with high-risk acute lymphoblastic leukemia after a stem cell transplant. The modified T cells are designed to target and kill leukemia cells, while the vaccine may help boost the immune response. The main goals are to check for side effects and see if the treatment can be given as planned.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CMV-specific CD19-CAR T cells and CMV-MVA triplex vaccine
What this could lead to: If it works, this could point toward a safer way to prevent leukemia relapse after a stem cell transplant.
What could go wrong: This is a very early, small trial (15 people) focused on safety. The treatment may not work or could cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.